Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-12
2007-06-12
McKenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S228800, C514S252010, C514S256000, C514S277000, C514S364000, C514S365000, C514S372000, C514S378000, C514S399000, C514S406000, C514S427000, C514S432000, C514S451000, C544S008000, C544S066000, C544S098000, C544S215000, C544S335000, C544S336000, C544S403000, C548S146000, C548S214000, C548S215000, C548S252000, C548S260000, C548S303100, C548S336500, C548S337100, C548S373100, C548S570000, C549S078000, C549S315000, C549S315000
Reexamination Certificate
active
10456399
ABSTRACT:
The present invention provides novel dialkylhydroxybenzoic acid derivatives containing metal chelating groups and the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species and/or excess Zn ions, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds of the invention have not only low toxicity but also similar or superior LPO inhibition activity to references. They also effectively inhibit the cerebral neuronal cell death by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.
REFERENCES:
patent: 2401522 (1946-06-01), Stoll et al.
patent: 4052361 (1977-10-01), Susi et al.
patent: 4908363 (1990-03-01), Klötzer et al.
patent: 5008394 (1991-04-01), Günther et al.
patent: 5510478 (1996-04-01), Sabb
patent: 5827880 (1998-10-01), Malfroy-Camine et al.
patent: WO98/08831 (1998-03-01), None
patent: 2002372625 (2002-12-01), None
Bray et al, Chemical Abrstract, vol. 42 No. 2961, “Fate of certain organic acids and amides in the rabbit”, (1947).
Mandel et al Jol. Nutri. BioChem. vol. 16 pp. 513-520 (2005).
Boldyrev et al Comp. BioChem. & Physio. Part B vol. 137 pp. 81-88 (2004).
Aksenova et al Jol. Neuor Sci. Res. vol. 58 pp. 308-317 (1999).
Parnetti, L. et al., Cognitive Enhancement Therapy for Alzheimer's Disease, Drugs, 53:752-768 (1997).
Grisa J. M. et al., 2,3-Dihydro-1-benzofuran-5-ols as Analogues of α-Tocopherol That Inhibit in Vitro and ex Vivo Lipid Autoxidation and Protect Mice against Central Nervous System Trauma, J. Med. Chem., 38:453-458(1995).
Thomas G. Back and Brian P. Dyck, A Novel Camphor-Derived Selenenamide That Acts as a Glutathione Peroxidase Mimetic, J. Am. Chem. Soc., 119:2079-2083 (1997).
Sies, et al., Ebselen as a Glutathione Peroxidase Mimic and as a Scavenger of Peroxynitrite, Adv. Pharmaco., 38:229-246 (1997).
Koh, et al., The Role of Zinc in Selective Neuronal Death after Transient Global Gerebral Ischemia, Science, vol. 272, 1013-1016 (1996).
Kim, et al., Zinc-Induced Cortical Neuronal Death with Features of Apoptosis and Necrosis: Mediation by Free Radicals, Neuroscience, 89:175-182 (1999).
Ashley I. Bush, The Metallobiology of Alzheimer's disease, Elsevier, TRENDS in Neurosciences vol. 26, No. 4, Apr. 2003, pp. 207-214.
Ashley I Bush, Metal complexing agents as therapies for Alzheimer's disease, Elsevier, Neurobiology of Aging, vol. 23, 2002, pp. 1031-1038.
Chang In-Kyu
Choi Dennis W.
Dugan Laura L.
Kim Kyung-Hwa
Ko Sung-Bo
Covington Raymond
Knobbe Martens Olson & Bear LLP
McKenzie Thomas
Samsung Electronics Co,. Ltd.
LandOfFree
Dialkylhydroxybenzoic acid derivatives containing metal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dialkylhydroxybenzoic acid derivatives containing metal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dialkylhydroxybenzoic acid derivatives containing metal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809504